Pulmonary Hypertension

aPL Antibodies Common in Chronic Thromboembolic Pulmonary Hypertension

aPL Antibodies Common in Chronic Thromboembolic Pulmonary Hypertension

By

Antiphospholipid antibodies are commonly found in patients with chronic thromboembolic pulmonary hypertension and may be predictive biomarkers for the disease.

Differentiating Between Acute Pulmonary Embolism and CTEPH Using Dual-Energy CT

Differentiating Between Acute Pulmonary Embolism and CTEPH Using Dual-Energy CT

By

Compared with patients with a negative CT, patients with chronic thromboembolic pulmonary hypertension tended to have lower dual-energy computed tomography-based parenchymal attenuation in Hounsfield unit.

Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals

Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals

By

In distinct situations with clear treatment goals, such as in candidates for lung transplantation, extracorporeal membrane oxygenation should be considered.

Fucoidan: A Potent Natural Adjuvant Representing a Possible Therapy in PAH

Fucoidan: A Potent Natural Adjuvant Representing a Possible Therapy in PAH

By

Chronic hypoxia-exposed mice that were given fucoidans exhibited improved vascular remodeling and right ventricular function.

Endothelial Colony Forming Cells in PAH Restore Myocardial Vascular Density

Endothelial Colony Forming Cells in PAH Restore Myocardial Vascular Density

By

In patients with pulmonary arterial hypertension, endothelial colony forming cell transplantation was associated with restoration of myocardial vascular density.

Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH

Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH

By

LIQ861, an inhaled dry powder formulation of treprostinil, was well tolerated in patients with pulmonary arterial hypertension at a 2-week time point in the phase 3 clinical trial, INSPIRE.

Elevated Myocardial T1 Associated With Increased Septal Angle in PAH

Elevated Myocardial T1 Associated With Increased Septal Angle in PAH

By

Elevated levels of myocardial native T1 are associated with increased interventricular septal angle in patients with pulmonary hypertension.

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH is an under-diagnosed complication of adult-onset Still disease.

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

By

Combinations of VO2 and change in CI during follow-up visits are valuable prognosis markers in low-risk patients with PAH.

Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?

Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?

By

Pre-existing pulmonary hypertension does not appear to affect outcomes in transcatheter mitral valve repair with the Mitraclip device.

Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

By

Systemic sclerosis-associated pulmonary hypertension and systemic sclerosis-associated interstitial lung disease exhibit similar but distinct gene expression profiles.

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

By

Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.

Patient Age Linked With Specific PAH Clinical Profile and Prognosis

Patient Age Linked With Specific PAH Clinical Profile and Prognosis

By

Patients with pulmonary hypertension age ≥65 years have worse long-term survival compared with younger patients.

Exercise Capacity in CTEPH Improved With Treprostinil

Exercise Capacity in CTEPH Improved With Treprostinil

By

Compared with the low dose, high-dose subcutaneous treprostinil increased 6-minute walk distances in patients with chronic thromboembolic pulmonary hypertension.

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

By

People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease Subtypes

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease Subtypes

By

Because standardized approaches for echocardiographic screening are impractical for certain subgroups of people with congenital heart disease, experts offered screening adaptations for pulmonary hypertension.

Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

By

Pulmonary thromboendarterectomy appears to be a curative resolution in patients with antiphospholipid syndrome related to chronic thromboembolic pulmonary hypertension.

Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

By

Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.

Pulmonary Vascular Disease and Late Respiratory Disease Link in Preterm Infants

Pulmonary Vascular Disease and Late Respiratory Disease Link in Preterm Infants

By

Preterm infants who need mechanical ventilation at day 7 and early echocardiographic evidence of pulmonary vascular disease are strong risk factors for late respiratory disease.

Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

By

At follow-up, the 6-minute walk distance, cardiac index, stroke volume index, and other hemodynamic variables were independently associated with transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension.

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

By

Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

By

Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.

Macitentan Tolerated in Portopulmonary Hypertension

Macitentan Tolerated in Portopulmonary Hypertension

By

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

By

In some patients at risk for pulmonary hypertension, left ventricular end diastolic pressure measurement with standard right heart catheterization should be used.

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

By

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

By

United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.

Segmental Pulmonary Hypertension: Management of New Classification

Segmental Pulmonary Hypertension: Management of New Classification

By

Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

By

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

By

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

By

Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.

Sign Up for Free e-newsletters